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Abstract
The introduction of the classification of brain tumours based on their DNA methylation profile has significantly changed the
diagnostic approach for cases with ambiguous histology, non-informative or contradictory molecular profiles or for entities
where methylation profiling provides useful information for patient risk stratification, for example in medulloblastoma and
ependymoma. We present our experience that combines a conventional molecular diagnostic approach with
the complementary use of a DNA methylation-based classification tool, for adult brain tumours originating
from local as well as national referrals. We report the frequency of IDH mutations in a large cohort of nearly
1550 patients, EGFR amplifications in almost 1900 IDH-wildtype glioblastomas, and histone mutations in 70
adult gliomas. We demonstrate how additional methylation-based classification has changed and improved
our diagnostic approach. Of the 325 cases referred for methylome testing, 179 (56%) had a calibrated score
of 0.84 and higher and were included in the evaluation. In these 179 samples, the diagnosis was changed in
45 (25%), refined in 86 (48%) and confirmed in 44 cases (25%). In addition, the methylation arrays contain
copy number information that usefully complements the methylation profile. For example, EGFR amplification
which is 95% concordant with our Real-Time PCR-based copy number assays. We propose here a diagnostic
algorithm that integrates histology, conventional molecular tests and methylation arrays.
Keywords: IDH1, IDH2, BRAF, Histone mutation, H3 K27M, Methylation array, Illumina array, DKFZ classifier,
Methylation classifier, Molecular diagnostics, Glioma, Ependymoma, Brain tumour classification, Adult brain
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Introduction
The diagnosis of brain tumours is achieved by combin-
ing morphological features, immunohistochemical (IHC)
detection of lineage-related markers, and more recently
by the detection of genetic biomarkers, for example mu-
tations in the isocitrate dehydrogenase genes 1 and 2
(IDH1 and IDH2) [1, 13], BRAF [35], or histone genes
[16]. The development of mutation-specific antibodies
to the most common IDH1 mutation R132H [5], BRAF
V600E [3] or Histone H3 K27M [6] has facilitated the
introduction of these tests into routine neuropathology
diagnostics and their use is our first diagnostic step. To
refine the diagnostic accuracy, we use Sanger sequen-
cing, for example to detect rarer mutations in the IDH1,
or IDH2 genes [26], histones [16], or to detect mutations
in the TERT promoter either to support glioma diagnos-
tics in the context of other mutations [10] or to prog-
nosticate meningioma recurrence risk [33]. Yet, a
significant number of CNS tumours still lack distinctive,
and diagnostically informative mutations that can be
readily implemented into routine diagnostic practice, or
such tests (e.g. gene fusion tests covering multiple break-
points) may be resource-intensive to set up, validate and
to test routinely. Therefore, neuropathologists may be
tempted to revert to the traditional approach of tumour
typing and grading, which is fraught by considerable
intra-, and inter-observer variability, and by a lack of
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robust clinical-pathological correlation. For example, it
is well established that grading based on histological fea-
tures such as mitotic counts, cellularity, pleomorphism,
vascular abnormalities and necrosis do not correlate well
with the clinical outcome in ependymomas [24] or in
diffuse gliomas [38]. The prognostication of intrinsic
brain tumours based mainly or exclusively on morph-
ology can be misleading, as for example shown in a
large-scale study on IDH-wildtype low-grade astrocyto-
mas, where a small proportion was confirmed to be of
low-grade, whilst a much larger proportion corre-
sponded molecularly to high-grade gliomas [29]. The
ambiguity of traditional histopathological criteria to in-
form clinical oncologists on patient management, and
the patients of the prognosis, called for a radically new
approach for tumour diagnostics, leading to the develop-
ment of a comprehensive CNS tumour reference cohort
based on genome-wide DNA methylation profiles [2, 4].
Methylation profiles of tumours result from a combination
of somatically acquired DNA methylation changes and the
cell of origin [11]. These profiles are highly robust and repro-
ducible in clinical pathology settings [15] and have been
widely used to subclassify CNS tumours, for example epen-
dymomas [25], meningiomas [34], medulloblastomas [15],
nerve sheath tumours [31], primitive neuroectodermal tu-
mours [40] or other tumour types such as “small blue round
cell tumours” [17]. A brain tumour methylation classifier has
been developed at the German Cancer Research Center
(DKFZ) and Heidelberg University in Heidelberg, Germany
(henceforth in short “Classifier”), to identify distinct DNA
methylation classes of CNS tumours. Currently, the Classifier
comprises 82 CNS tumour methylation classes and nine
control tissue methylation classes [2]. The Classifier has been
made available through a free online tool (www.molecular-
neuropathology.org). We have used this classification tool [2,
4] in clinical practice to stratify into clinically relevant risk
groups of histologically defined CNS (and related) tumour
entities, and as an aid to establishing a diagnosis in histologi-
cally uncertain cases, for example when morphology, loca-
tion and demographics were highly unusual, the histology
non-specific, or where molecular tests were contradictory,
ambiguous or non-informative. We have analysed more than
500 tumours using Illumina 450K or 850K EPIC methyla-
tion arrays, followed by algorithmic classification with the
Classifier. Here we present the implementation of this plat-
form in a neuropathology department within a major aca-
demic health science centre, and our experience using the
Classifier in routine clinical diagnostic practice.
Material and methods
The rationale for methylation profiling and tumour
selection
Methylation profiling was set up in the Division of
Neuropathology, the National Hospital for Neurology
and Neurosurgery (NHNN) at University College
London Hospitals NHS Foundation Trust, a large clin-
ical centre for neurological disorders of adults. Tumours
included in this study were analysed with methylation
arrays between February 2015 and November 2018.
Samples included in this study originated from our
own hospital (NHNN) or were referred to us for a sec-
ond opinion or conventional and advanced molecular
profiling. All tumours underwent routine histopatho-
logical assessment, including immunohistochemical and
molecular examination in our centre or by referring pa-
thologists, and then were processed for methylation ar-
rays. The entry criteria for methylation profiling of
diagnostic samples were not strictly predefined but were
guided by a routine diagnostic decision-making process.
A proportion of cases was profiled in the context of re-
search studies or clinical trials, and these were not in-
cluded in this study.
The cases submitted for the methylation arrays were
categorised into six groups with the following character-
istics: (i) unusual combination of morphology, location
and demographics, (ii) contradictory, ambiguous or
non-informative molecular tests, (iii) confirmation of
unusual histological and molecular results, (iv) small bi-
opsy or non-representative sample, (v) indistinct or
non-specific histological appearance, and (vi) cases with
characteristic histology requiring risk stratification, such
as medulloblastoma [41] or ependymoma [24].
In order to gain experience with the implementation of
the technology in our laboratory, and to correlate clinical,
pathological and molecular features with the results of the
Classifier; a proportion of tumours with clearly defined
(molecular) biomarker profile was used to set up and val-
idate the procedures. During our setup phase, the Classi-
fier was also used for re-classification of tumours
previously diagnosed as oligoastrocytoma, which has been
discontinued as a distinct entity [30, 32, 42], or tumours
with the histological phenotype of adult primitive neu-
roectodermal tumour (PNET) which now resolve into
multiple different entities [40].
Specimen preparation and quality control
All tissues used for methylation studies were fixed in
formalin for at least 4 h, and larger samples were dis-
sected and fixed overnight, followed by processing
through graded alcohols and xylene, to paraffin accord-
ing to standard practice in an ISO15189 accredited la-
boratory. Tissue embedding and sectioning were
according to standard histopathology procedures.
Selection of tumour area
Sections of the formalin fixed paraffin embedded (FFPE)
samples selected for methylation array analysis were
mounted on glass slides (by default 10 μm thickness, 8
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consecutive slides). On a consecutive H&E stained sec-
tion (3–4 μm), a suitable tumour area was identified by a
neuropathologist (SB or ZJ), to maximise inclusion of vi-
able tumour-containing tissue. Tumour content of at
least 80% was selected where possible and non-neoplas-
tic tissue, blood or excessive areas of necrosis were ex-
cluded. However, on some occasions where the
specimen contained an overall lower tumour density
(e.g. infiltration zone) a methylation array analysis was
nevertheless attempted, acknowledging a potential risk
of an inconclusive Classifier result.
DNA extraction and quantification
Slides with mounted tissue were dewaxed (3 washes in
xylene and 2 washes with industrial methylated spirit)
and air-dried. Tissue selected for the analysis was
scraped off and collected in lysis buffer and DNA was
extracted with the Maxwell 16 Lev FFPE DNA Purifica-
tion Kit on a Maxwell 16 extractor [19]. The DNA ex-
traction procedure was carried out according to manual
#TM349 for DNA extraction (Promega). DNA was then
quantified and A260/A280 ratios were determined on a
Nanodrop 8000 Spectrophotometer (ThermoFisher). An
A260/A280 ratio of ~ 1.8 was considered to represent suf-
ficient purity to proceed with the methylation study.
However, rarely we also process samples with a lower
A260/A280 ratio if there is a clinical necessity and no add-
itional material available to repeat extraction or
purification.
In our practice, tissue size and resulting DNA amount
was rarely the limiting factor. Even a single core of a
small stereotaxic biopsy, extracted from 8 consecutive
sections of 10 μm thickness yielded well above the rec-
ommended minimum of 250 ng. A single core of ap-
proximately 4 mm2 (calculated tissue volume 0.34 mm 3)
has yielded 600 ng of high-quality DNA, and slightly lar-
ger cores of 10–12mm2 (calculated tissue volume 0.8–
0.9 mm3) have yielded 1400–1800 ng DNA, i.e. well
above 250 ng. All these examples were processed and
returned a result with a calibrated score of 0.99. In our
practice we aim at a DNA input of 500 ng, and in our
experience a limiting factor is more often the tissue (and
resulting DNA) quality, or tumour content, rather than
sample size.
FFPE tissue quality control (QC) assay
Real-time PCR (RT-PCR) assays were run with technical
triplicates using DNA isolated from FFPE samples and a
QC standard, using primers supplied in the Illumina
Infinium HD FFPE QC Kit (Infinium HD FFPE QC
Assay Protocol, Illumina). The quality cycle threshold
(QCT) value was calculated by subtracting the average
Cq of Illumina QC standard from the average Cq value
determined for each FFPE sample. Illumina recommends
that a QCT value ≤5 be utilized for optimal assay
performance.
Bisulphite conversion of DNA
Based on the DNA quantification steps as determined
previously, we aim at an input of 250 ng as a minimum,
and ideally at 500 ng DNA from each sample for bisul-
phite conversion. The EZ DNA Methylation™ Kit (Zymo
D5024) was used for DNA conversion. All steps were
performed according to the manufacturer’s guidelines.
Copy number assays and sequencing
DNA for copy number assays or direct sequencing was ex-
tracted from FFPE tumour tissue using Maxwell 16 FFPE
LEV DNA purification kit (Promega). Tumour area was
confirmed on an H&E-stained slide and tissue was micro-
dissected from consecutive 10 μm FFPE sections. Primer
design was as follows: IDH1-F ACCAAATGGCACCA
TACGA; IDH1-R TGCTTAATGGGTGTAGATACCA
AA; IDH2-F CCAATGGAACTATCCGGAAC; IDH2-R
TGTGGCCTTGTACTGCAGAG, BRAF 600-f TCAT
AATGCTTGCTCTGATAGGA; C600-r GGCCAAAAA
TTTAATCAGTGGA, TERT-f AGTGGATTCGCGGG
CACAGA, TERT-R; Histone H3F3-F CATGGCTCG
TACAAAGCAGA, H3F3-R CAAGAGAGACTTTG
TCCCATTTTT. For all copy number assays we used the
Comparative CT (threshold cycle) multiplex PCR (in same
tube) method (ΔΔCT) [36]. The following probes were
used for target and reference genes, respectively: 1p36.12b
(assay ID Hs06545466_cn; RnaseP 4401631), 1p13.3a
(assay ID Hs01847890_cn; RnaseP 4401631); 19q13.2b
(assay ID Hs00954642_cn; RnaseP 440163); 19q13.42c
(assay ID Hs00831101_cn; RnaseP 440163); 10q23.31a
(assay ID Hs05203872_cn; RnaseP 440163); 7p11.2c (assay
ID Hs01381289_cn; TERT 4401633). Calibrators were
commercial human genomic DNA (gDNA) at a concen-
tration of 10 μg/μl, (Human Genomic DNA (Male), Pro-
mega, G147a) and mixed DNA (mDNA), which contains
1:3 dilution of the gDNA. Copy numbers were determined
with the CopyCaller® Software v2.1 (Applied Biosystems).
Immunohistochemistry
All IHC stainings were carried out on automated immu-
nostainers (Roche Ventana Discovery or LEICA Bond-
Max) following manufacturer’s guidelines. The IDH1
R132H, BRAF V600E, H3 K27M and ATRX antibodies
were used as published [3, 6, 30].
Performing Infinium FFPE restoration
Degraded FFPE DNA was restored into an amplifiable
condition with the Infinium HD FFPE DNA Restore Kit
(24 samples, WG-321-1002) according to the manufac-
turer’s instructions.
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Array processing
The 450 k or EPIC (850 k) methylation array was used to
obtain genome-wide DNA methylation profiles for FFPE
tumour samples, according to the manufacturer’s in-
structions (Illumina). DNA methylation data were gener-
ated at the UCL genomics facility at UCL Institute of
Child Health. On-chip quality metrics of all samples
were carefully controlled. Data (idat files) were trans-
ferred to the Division of Neuropathology and uploaded
to the Classifier (www.molecularneuropathology.org).
Following the upload, the classification result was
returned automatically as reported [2].
Results and discussion
Definition of outcomes and calibrated score
For best comparison with other datasets, we aligned the
definitions closely to the initial publication of the classi-
fication tool [2]. The outcomes were classified according
to the impact on the original pathological diagnosis: ori-
ginal pathology confirmed (outcome 1), refined (out-
come 2) or a new diagnosis established (outcome 3).
Alternatively, the Classifier result was considered mis-
leading (outcome 4) or inconclusive (outcome 5)
(Fig. 1a and Table 1). The frequency of outcome 4 or 5
depends on the threshold of the calibrated score. We in-
cluded in our analysis only results with a calibrated
score of 0.84 and above as recommend in [4]. Classifier
results with a calibrated score below 0.84 can still yield
informative results [4], in particular when taking into ac-
count copy number profiles (such as 7p gain; 10q loss in
IDH-wildtype glioblastoma, 1p/19q codeletion in
IDH-mutant oligodendroglioma, or copy number vari-
ation and CDKN2A/B deletions in IDH-mutant astrocy-
tomas). Calibrated scores are class probability estimates
that measure confidence in the prediction. If the score
calibrated is working perfectly, among all tumours of a
“Class X” with a score of 90%, there will be 90% “Class
X” tumours. A low score indicates that the classifier is
uncertain in its prediction and thus these predictions are
often false. Otherwise, if most of the low score predic-
tions were true, the probability estimation (or score cali-
brated) would not work correctly.
Confirmation of diagnosis (outcome 1): this category
includes cases in which the Classifier confirmed the inte-
grated diagnosis, such as IDH-mutant and 1p/19q
co-deleted oligodendroglioma, IDH-mutant glioblast-
oma, subependymoma, H3 K27M-mutant diffuse mid-
line glioma, and similar. This category also comprises
tumour entities where histology or location of a tumour
is unusual.
Refinement of diagnosis (outcome 2): this category
includes cases in which the Classifier confirms the histo-
logical or integrated diagnosis, and determines a more
specific molecular subtype, for example in IDH-wildtype
glioblastoma, ependymoma or medulloblastoma. It also
includes cases where the diagnostic accuracy is im-
proved, e.g. confirmation of an IDH-mutant oligo-
dendroglioma with previously tested ambiguous 1p/19q
result or sub-classification of tumours with non-specific
low-grade morphology, such as IDH-wildtype low-grade
glioneuronal tumours.
Establishing a new diagnosis (outcome 3): this out-
come was assigned to indicate a change of the original
diagnosis (usually unexpected, for example, the change
from the histological diagnosis of an ependymoma to
the methylation class of a pleomorphic xanthoastrocy-
toma, PXA). The main reasons for this outcome were (i)
morphologically inconclusive specimens (e.g. with a
diagnosis of low-grade or high-grade glioma, with no
specific molecular alterations detectable by conventional
molecular methods), for which a conclusive methylation
class could be established; (ii) incorrect histological in-
terpretation, where relevant tests were not considered as
a consequence (e.g. solitary fibrous tumour/haemangio-
pericytoma misdiagnosed as meningioma); (iii) a distinct
histological pattern does not correspond to a specific
methylation class (e.g. a tumour with the pattern of
astroblastoma often but not always belongs to the
HGNET_MN1 methylation class); (iv) all tumours with
a newly defined methylation class that do not corres-
pond to an existing WHO entity (e.g. “primitive neu-
roectodermal tumour” (PNET) resolving into multiple
newly defined entities).
Misleading profile (outcome 4): in our experience,
there are two scenarios in which misleading results can
occur. A low calibrated score can result in a methylation
class that is inconsistent with previously tested molecu-
lar markers and histology. For example, the methylation
class IDH-wildtype glioma in a previously confirmed
IDH-mutant glioma. A high calibrated score of > 0.84
rarely generates misleading results. In our 325 diagnostic
samples, 179 (56%) had a calibrated score of > 0.84 (Fig.
1b) and none of these showed a misleading profile.
Inconclusive or non-contributory profile (outcome
5): was assigned to cases that showed an obvious dis-
crepancy between the input material and the methyla-
tion class (such as normal control tissue in cases where
analysed material was of a tumour) or in cases where
the methylation profiling did not provide any additional
diagnostic information. In cases with calibrated score >
0.84 we encountered four cases with a non-contributory
profile.
Integration of methylation classification into the
diagnostic process
Below we outline our diagnostic workflow and decision-
making process for adult CNS tumours, incorporating
the use of methylation arrays and the Classifier. Our
Jaunmuktane et al. Acta Neuropathologica Communications            (2019) 7:24 Page 4 of 18
AB
C
Fig. 1 (See legend on next page.)
Jaunmuktane et al. Acta Neuropathologica Communications            (2019) 7:24 Page 5 of 18
department receives diagnostic samples through
three pathways: (i) the local hospital (NHNN) refers
tissue for the complete diagnostic workup (tissue
diagnosis, molecular diagnostics (pathway 1)); (ii)
two geographically separate clinical centres refer
formalin-fixed tissue for complete workup as above
(pathway 2); and (iii) direct referral of externally di-
agnosed tumours for advanced molecular workup,
often with a specific request to perform methylation
array analysis (pathway 3).
Turnaround times
An important consideration for clinical utility is the
turnaround time of tests. The turnaround times
(TAT) of methylation arrays are partly dictated by the
necessity to form batches (12 arrays on the 450 k
chips, and 8 arrays on the 850 k chips), the time it
takes to process chips, and how often arrays are proc-
essed in a genomics facility. The TAT also depends
on the accrual rate of samples. Figure 1c shows a
graphical representation of the TAT (the time re-
quired from ordering the test in the laboratory to re-
ceiving the data files for the upload on the webpage).
Figure 1c shows our institutional performance be-
tween 2015 and 2018, demonstrating a relatively sig-
nificant variation in sample throughput (which is
directly proportional to the number of requested
tests) and the TAT. Over time, practice and workflow
optimisation has reduced the proportion of samples
with TAT exceeding 30 days.
Cost implications
Using list prices for arrays and conversion kits and facil-
ity fees, processing of one sample incurs a cost of ap-
proximately £380 as of November 2018, without
applying discounts that are currently available to our in-
stitution. These are itemised as follows: Microarray
WG-317-1003 £267 per sample for orders of 96 samples;
FFPE restore Kit WG-321-1002 £64 per sample (kit for
24 samples), salary cost for sample registration, DNA ex-
traction, bisulphite conversion, quality control, data up-
load and results download (8 h @ £50/h = £400, or £50
per sample). This does not include time for medical staff
to report cases, taking approximately 30–45min per
case. We consider methylation arrays as a cost-effective
and tissue-saving approach for diagnostically challenging
cases. A single IHC section costs approximately £18 (full
economic costing) and methylation arrays are likely to
yield significantly more information and thus better
value for money than large panels of immunostains. In
our practice, where methylation arrays are readily avail-
able and embedded in the diagnostic pathway we usually
do not perform more than 10 immunostainings on in-
trinsic tumours, as additional stains are unlikely to add
meaningful information. An even lower threshold (as
few as 3–5 immunostains) is applied to small, precious
samples such as stereotaxic biopsies, and targeted se-
quencing and methylation arrays are considered early in
the diagnostic workup. However, for the routine molecu-
lar diagnostics where such limitations do not apply,
methylation arrays are not yet the first choice: the con-
sumable cost for Sanger sequencing and copy number
(See figure on previous page.)
Fig. 1 a, the association of methylation array testing rationale (left) with the outcome of the methylome-based classification (right). 179 cases
with a calibrated score of 0.84 and higher were included in this graph. b, distribution of calibrated scores in 325 diagnostic samples examined
(excluding research samples) demonstrating that for > 55% (179/325) of the predictions the classifier has had high confidence with estimated
class probabilities of 94 > 99%. c, Scattergram of turnaround times (TAT) of tests between 2015 and 2018. Whilst the TAT in the first 2 years of the
setup phase often comprised 50% of latencies over 30 days, these long TAT have been progressively reduced in 2018. In quarters 2–4 of 2018,
the majority of the cases was completed within 4 weeks. For the first four months in 2015 we did not record the dates of requesting tests,
therefore no TAT are shown between February and June 2015
Table 1 Number of cases referred for methylation array analysis and the proportion of cases with a calibrated score of 0.84 and
higher, and the proportion of cases in which the diagnosis was changed, refined, or confirmed or where the test yielded non-
contributory results
Number of cases Proportion of all cases Proportion of cases with CS > 0.84
Cases referred for testing 325 100% 56%
Tumours with a calibrated score > 0.84 179 56% 100%
Establishing new diagnosis 45 14% 25%
Refinement of diagnosis 86 26% 48%
Confirmation of diagnosis 44 14% 25%
Non-contributory 4 1% 2%
CS Calibrated score
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assays is a fraction of those for methylation arrays, and
the turnaround times are significantly shorter, making it
impractical and unaffordable to implement methylation
arrays for the diagnosis of all brain tumours.
Local tissue referrals (pathways 1 and 2): all brain
tumours undergo routine histological and immunohisto-
chemical examination and are reported as part of the
standard diagnostic process in our department. Low-
and high-grade gliomas and poorly differentiated supra-
tentorial intrinsic tumours with PNET morphology
undergo immunostaining for IDH1 R132H and ATRX.
IDH-mutant tumours with ATRX loss are diagnosed as
IDH-mutant astrocytomas or glioblastomas (GBM), and
for prognostication, these are tested for CDKN2A/B
homozygous deletion [38]. IDH-mutant tumours with
retained ATRX undergo further testing for 1p/19q and
TERT promoter mutations. Midline gliomas are rou-
tinely tested with immunostaining for H3 K27M. IDH1
R132H negative gliomas undergo a targeted sequencing
for known mutations in the IDH1/2, histone H3.3
(H3F3A), BRAF genes and the TERT promoter, and copy
number assays (1p/19q, CDKN2A/B, 7p (EGFR), and
10q (PTEN locus)). This identifies the remaining
IDH- or histone-mutant gliomas and IDH-wildtype,
TERT-mutant, and/or EGFR amplified GBM. IDH- and
histone-wildtype gliomas with ATRX loss also undergo
BRAF fusion testing to identify possible anaplastic astrocy-
toma with piloid features [28].
Tumours with unusual location or non-specific glial or
glioneuronal morphology and non-informative conven-
tional molecular test results are then considered for
methylation arrays. In this study, the threshold to use
the Classifier was lower for young adults, although we
did not define a specific age cut-off and instead made a
case-based decision in consultation with the clinical
teams. The Classifier was also used for confirmation of
rare tumour entities which do not have any of the
above-mentioned gene mutations. The methylation class
was reported as part of the integrated diagnosis, e.g.
“histology: low-grade glioma, IDH-wildtype; methylation
class: glioblastoma, IDH-wildtype RTK II”; or “histology:
high-grade glioma; methylation class: pleomorphic
xanthoastrocytoma; BRAF V600E mutant”.
All supra- and infratentorial ependymomas undergo
methylation studies. We encounter a relatively small
number of supratentorial ependymomas in our adult
practice (in this cohort, from pathways 1 and 2 n = 7),
which in our view justifies initial risk stratification by
methylation profiling [12] instead of nucleic acid-based
tests for multiple potential gene fusion transcripts. Tu-
mours with characteristic subependymoma morphology
irrespective of location and all spinal ependymomas are
not tested further unless there is a specific clinical re-
quest, an unusual clinical presentation, or histology.
Infratentorial tumours with features of embryonal tu-
mours (e.g. medulloblastoma), similar to ependymomas,
typically are processed for methylation array for risk
stratification purposes, although the prognostic signifi-
cance of medulloblastoma subclasses in adults is cur-
rently not firmly established. Since April 2018, all adult
medulloblastomas in the UK are referred to the National
Medulloblastoma Reference Centre through Great
Ormond Street Hospitals [37].
Pilocytic astrocytomas are routinely tested for BRAF
V600 and the three most common KIAA1549:BRAF fu-
sion mutations (16–9, 16–11, 15–9). Tumours with a
confirmed mutation are not further investigated. Tu-
mours with pilocytic astrocytoma or other low-grade
glial or glioneuronal morphology with no BRAF V600
mutation, absence of the three tested fusions, and in par-
ticular, those with loss of ATRX protein expression rou-
tinely undergo methylation array testing.
Referrals of previously diagnosed tumours (pathway
3) are (i) specifically referred for Illumina array analysis,
or received for (ii) targeted diagnostics with conven-
tional molecular tests as above, or (iii) second opinion,
often with extensive previous workup, including molecu-
lar testing. Cases which remain inconclusive after the
molecular studies are then processed for methylation ar-
rays and an integrated diagnosis is returned to the refer-
ring pathologists.
Diagnostic outcomes from molecular assays in our
practice
IDH-mutant gliomas
The most common reason for further workup with
methylation array is a confirmed IDH mutation in com-
bination with an inconclusive ATRX, TERT promoter
and 1p/19q status; for example IDH-mutant gliomas
with retained ATRX expression and ambiguous 1p/19q
status; or rare diffuse gliomas with ATRX loss in which
the IDH- or histone H3 mutation cannot be established
by IHC or sequencing.
In order to establish if an upper age limit can be justified
for the testing of IDH1/IDH2 mutations beyond the use of
immunostaining with the IDH1 R132H mutation-specific
antibody, we analysed the age distribution in 1546 tu-
mours. The frequency distribution of the distinct IDH1
and IDH2 mutations is comparable to previous reports of
similar scale [13] (Fig. 2). In addition to mutations de-
scribed in previous series [7, 14, 26] we found rare muta-
tions such as IDH2-G515C (R172T), IDH2-G516C
(R172S), IDH2-G516T (R172S), IDH2-A514G (R172G),
and IDH2-G515T (R172M) in astrocytomas and oligo-
dendrogliomas, and we found a single case with a silent
mutation IDH2-G516A (R172R). In keeping with previous
studies [13, 23] in our cohort, 243 (15.7% of the entire co-
hort) of IDH-mutant gliomas occurred in patients aged
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55 years and older (Fig. 3), of which 31 (13%) would not
have been detected by IDH1 R132H IHC alone. In our
opinion, this justifies molecular testing for these rarer
IDH1/IDH2 mutations in patients over 55 years, in con-
trast to previous recommendations [9, 22].
As previously shown [20] and in our experience, there
is a small subset of IDH-mutant, 1p/19q non-co-deleted
tumours with retained ATRX protein expression. These
tumours correspond to methylation class “IDH-mutant
astrocytoma, high-grade”, in keeping with earlier studies
[18]. Importantly, mutations in TERT promoter may be
observed in these tumours [18].
We and most other centres use ATRX IHC as a surro-
gate marker for ATRX mutations, however, the loss of
function mutations with retained protein expression are
not detected [21]. As shown in our cohort and other
studies [21], such mutations are relatively infrequent but
provide an explanation for the discrepancies between
ATRX sequencing and immunohistochemistry. Centres
with access to affordable next-generation sequencing
may consider testing such cases for the presence of a
mutation.
In our cohort, we observed mutations in the TERT
promoter in all IDH-mutant, 1p/19q co-deleted oligo-
dendrogliomas, where testing was successful. Although
the finding of TERT promoter mutation in IDH-mutant
glioma is helpful in confirming the diagnosis of an oligo-
dendroglial tumour, in our experience the sequencing of
TERT promoter mutation can be technically challenging.
If 1p/19q and TERT promoter testing remains inconclu-
sive, sometimes occurring in referred cases that under-
went different fixation protocols, we resort to further
analysis with the Classifier.
Histone H3-mutant gliomas
As part of the sequencing panel described above, in
2015 we introduced H3F3A testing in all low- and
high-grade gliomas. In our practice, all H3 K27M
A
B
Fig. 2 a, the frequency of IDH mutations in our cohort (n = 1546). Blue, IDH1 mutations; orange and red, IDH2 mutations. The IDH1/IDH2
frequency in our cohort is slightly skewed toward rarer mutations, due to a proportion of referrals received specifically for sequencing studies.
b, the frequency of IDH1 and IDH2 mutations and associated tumour types (n = 441 astrocytomas (of which 339 have IDH1-G395A); n = 363
oligodendrogliomas (of which 303 have IDH1-G395A)). Dark grey, astrocytomas; light grey, oligodendrogliomas. The mutations are sorted in
descending order by overall frequency, excluding the most common IDH1-G395A mutation. The graph confirms the established association of
certain mutations, in particular in the IDH2 gene, with oligodendroglial or astrocytic tumours
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mutant gliomas (n = 49) have been located in the mid-
line, its proximity, or there was an anatomical connec-
tion to the midline. Occasionally, the proximity to the
midline was post-hoc suggested after detection of the H3
K27M mutation. When a histone mutation is detected
(by sequencing or H3 K27M IHC), we currently do not
proceed to methylation array testing. Instead, midline
tumours with no H3 K27M mutation, with or without
ATRX loss, and no other specific findings on conven-
tional molecular testing undergo further methylation
studies. In our cohort, H3 mutant gliomas (K27M in
particular) manifest also in adults over 50 years (Fig. 4).
In our experience, loss of ATRX protein expression oc-
curs in nearly all (18/19; 95%) H3 G34 mutant gliomas
but only in a subset (19/45; 42%) of H3 K27M mutant
gliomas. Rarely, we observed biphasic patterns of ATRX
loss in H3 K27M (1 case) - and H3 G34R mutant gli-
omas (1 case) (Fig. 4). In another case of a recurrent
high-grade glioma with ATRX loss, the methylation class
was “H3 G34 mutant glioblastoma”, but we could not
identify any H3 G34 mutation on the H3F3A, HIST1H3B
and HIST1H3C genes. This raises the possibility that
there is a mutation in another, as yet unknown, H3
variant-encoding histone gene.
Brain tumours with loss of ATRX protein expression
In our cohort, the brain tumours with loss of ATRX
protein expression are IDH-mutant low- and
high-grade astrocytomas, H3 K27M and G34 mutant
gliomas, anaplastic pilocytic astrocytomas (methyla-
tion class ANA_PA, also termed anaplastic astrocyto-
mas with piloid features) [28], and rarely
IDH-wildtype glioblastomas, confirmed with the Clas-
sifier. Tumours with ATRX loss but no IDH or His-
tone mutation (by IHC or sequencing) generally
undergo methylation array testing.
Newly established methylation classes representing new
entities
In our cohort of 179 brain tumour cases with a cali-
brated score of > 0.84 from adolescents and adults (16
years and older) we have identified the following new
biological entities defined by methylation classes: CNS
high-grade neuroepithelial tumour with MN1 alteration
(HGNET, MN1) (n = 1, aged 19), [40], anaplastic astrocy-
toma with piloid features (ANA PA) (n = 9, aged 25–73)
[28], diffuse leptomeningeal glioneuronal tumour
(DLGNT) (n = 2, aged 38 and 46) [8] and low-grade gli-
oma with MYB alteration (LGG, MYB) (n = 2, aged 17
Fig. 3 Age distribution of IDH mutations in our cohort (n = 1546) demonstrates that 15.7% of all IDH1/IDH2 mutations occur in patients 55 years
and older, justifying routine testing for these mutations in this age cohort
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and 33) (Fig. 5). In keeping with previous reports,
these tumours had either non-specific low-grade or
high-grade astrocytic morphology, primitive small
cell histology, or appearances of histologically de-
fined entities of astroblastoma and pilocytic astrocy-
toma [8, 27, 28].
These new molecular entities were originally identi-
fied by DNA-methylation profiling and since then
have been found to have characteristic recurrent gen-
etic alterations. Therefore, whilst possible to diagnose
them with conventional molecular methods involving
DNA or RNA sequencing, in routine practice, in our
opinion, the DNA methylation-based diagnostic ap-
proach is efficient and cost-effective for their
identification.
IDH-wildtype gliomas with low-grade morphology
Forty-four tumours with glial or glioneuronal morph-
ology, without histological high-grade features (such
as hypercellularity, brisk mitotic activity, microvascu-
lar proliferation and/or necrosis) and without
mutations in the IDH1 (R132) or IDH2 (R172) or
BRAF (V600) genes were analysed with the Classifier
and had a calibrated score of 0.84 and higher. For 18
(41%) of these tumours, the Classifier returned the
diagnosis of IDH-wildtype glioblastoma, IDH-mutant
high-grade astrocytoma, anaplastic pilocytic astrocy-
toma or H3 K27M- or G34R/V-mutant glioma (the
discrepant IDH-mutant case was confirmed to carry
an IDH mutation on repeat sequencing). The
remaining 26 (59%) were classified as various
Fig. 4 Occurrence of histone H3.3 K27M- (upper panel) and H3.3 G34-mutant gliomas in our cohort and the association with ATRX protein loss.
Rarely, a biphasic pattern of ATRX expression is observed both in H3 K27M- and H3 G34R-mutant gliomas (light purple boxes). On one occasion
we have identified H3F3A G34V mutation (asterisk in the age group 16–20 years). In another recurrent high-grade glioma, both primary and
recurrent tumours were classified as H3 G34-mutant glioblastoma, although no mutations could be found in H3F3A, HIST1H3B and HIST1H3C
genes (asterisk in the age group 36–40)
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low-grade glial or glioneuronal tumour entities
(Fig. 6). The average age for tumours classified as
low-grade tumour entities was 30.8 years and for
those classified as high-grade tumour entities 53.6
years (Fig. 6).
IDH-wildtype gliomas with high-grade morphology
The majority of IDH-wildtype high-grade gliomas are
glioblastomas. Characteristic signatures are chromosome
7 gains and 10 losses, EGFR amplification and TERT
promoter mutation [39]. In the cohort of [39] 1788 out
of 4284 GBM (41.7%) were EGFR amplified (methylation
classes: GBM_MYCN, GBM_RTK_I, GBM_RTK_II,
GBM_RTK_III, GBM_MES, GBM_MID). In our cohort
(2010–2018), we found 749 out of 1888 (39.7%) EGFR
amplified GBM (6 and more copies), suggesting a nearly
identical prevalence. From September 2015 till June
2018, 509 glioblastomas were tested for both TERT pro-
moter mutations and EGFR status (Fig. 7). 121 were
TERT-wildtype and EGFR non-amplified, 211 were
TERT-mutant and EGFR non-amplified, 25 were TERT-
wildtype and EGFR amplified and 152 were TERT-mu-
tant and EGFR amplified. These data are largely compar-
able with a published dataset [39] (Fig. 7). In 41 cases of
IDH-wildtype glioblastoma, EGFR status was assessed
with both, methylation arrays and RTPCR. Only two
cases showed a discrepant result, where the
Illumina-derived plot showed amplification and the
RT-PCR result revealed a copy number corresponding to
non-amplified status, indicating a 95% concordance be-
tween both methods (χ2 0.21, p = 0.64), (Fig. 7).
A comprehensive table outlining a suggested diag-
nostic test algorithm, combining histology, immuno-
histochemical markers, conventional molecular tests
and methylation arrays in low-grade and high-grade
gliomas is shown in Fig. 8. We choose this approach
as the consumable cost for Sanger sequencing and
copy number assays are considerably below those of
methylation arrays (approximately 10% of the cost)
and the turnaround times allow for communication of
test results within approximately 7 working days.
Therefore, we choose methylation arrays as a
first-line approach typically for small biopsies for
which we predict an inconclusive outcome with our
“conventional” molecular test portfolio, and for cases
with an unusual histological presentation. In our rou-
tine practice, the first-line approach is usually as sug-
gested in Fig. 8.
Fig. 5 CNS tumours of varied histology resolving into new entities defined by their methylation profile. IDHwt: IDH-wildtype; GBM IDHwt: Glioblastoma,
IDH-wildtype; LGG NOS IDHwt: Low-grade glioma not otherwise specified, IDH-wildtype; LG-Glioneuronal: Low-grade glioneuronal tumour; PA: Pilocytic
astrocytoma; HGG NOS IDHwt: High-grade glioma not otherwise specified, IDH-wildtype; HGNET, MN1: CNS high-grade neuroepithelial tumour with MN1
alteration; ANA PA: Anaplastic pilocytic astrocytoma (anaplastic astrocytoma with piloid features); LGG, MYB: Low-grade glioma with MYB alteration; DLGNT:
diffuse leptomeningeal glioneuronal tumour
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Ependymal tumours
Ependymal tumours located supratentorial or in the
posterior fossa are submitted for the methylation ana-
lysis specifically for risk stratification purposes [24,
25] (Fig. 9). In our experience, the greatest
discrepancy between the histological diagnosis and
methylation class relates to the subependymoma en-
tity in tumours located in the posterior fossa (Fig. 10).
All but one ependymal tumour with the histology re-
ported as classical ependymoma, WHO grade II, had
Fig. 6 a, the outcome of methylation profiling of 44 IDH-wildtype CNS tumours with low-grade histology. Of these, 26 resolved into methylation
classes associated with low-grade behaviour, and 18 resolved into entities associated with high-grade behaviour. b, shows how various tumours
manifesting with low-grade histology resolve into distinct high-grade methylation classes. Abbreviations in a: LGG, GG: Low-grade glioma,
ganglioglioma; LGG, SEGA: Low-grade glioma, subependymal giant cell astrocytoma; LGG, RGNT: Low-grade glioma, rosette forming glioneuronal
tumour; LGG, DNT: Low-grade glioma, dysembryoplastic neuroepithelial tumour; LGG, MYB: Low-grade glioma with MYB alteration; LGG, PA PF:
Low-grade glioma, pilocytic astrocytoma in posterior fossa; LGG, PA/GG ST: Low-grade glioma, pilocytic astrocytoma ganglioglioma spectrum in
supratentorial compartment; A PA: Anaplastic pilocytic astrocytoma (anaplastic astrocytoma with piloid features); A IDH, HG: IDH-mutant high-
grade astrocytoma; GBM, G34: H3 G34-mutant glioblastoma; DMG, K27: H3 K27-mutant diffuse midline glioma; GBM, RTK II: IDH-wildtype
glioblastoma, RTK II subclass; GBM, MES: IDH-wildtype glioblastoma, mesenchymal subclass. Abbreviations in b: Glioma NOS IDHmt: IDH-mutant
glioma, not otherwise specified; LGG-Glioneuronal: Low-grade glioma or glioneuronal tumour; LGG NOS IDHwt: IDH-wildtype low-grade glioma
not otherwise specified; PA: Pilocytic astrocytoma; Neurocytoma, IDHwt: IDH-wildtype neurocytoma; PXA: pleomorphic xanthoastrocytoma; A IDH,
HG: IDH-mutant high-grade astrocytoma; ANA PA: Anaplastic pilocytic astrocytoma (anaplastic astrocytoma with piloid features); DMG, K27: H3
K27-mutant diffuse midline glioma; GBM, G34: H3 G34-mutant glioblastoma; GBM, MES: IDH-wildtype glioblastoma, mesenchymal subclass; GBM,
RTK II: IDH-wildtype glioblastoma, RTK II subclass
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a methylation profile of subependymoma. This finding
is in line with earlier recommendations [24] that
treatment decisions outside of clinical trials should
not be based on a histologically assigned WHO grade.
The Classifier also has helped in accurately diagnos-
ing a subependymoma of which only small amounts
of tissue were available, precluding a definitive histo-
logical diagnosis. An overview of the changes of
diagnosis for ependymal tumours is given in Fig. 10.
In another instance, the Classifier prompted us to
change the diagnosis from histologically diagnosed an-
aplastic ependymoma to a BRAF V600E-mutant pleo-
morphic xanthoastrocytoma. This tumour underwent
methylation array analysis specifically for the risk
stratification after resection of a recurrence of a pre-
sumed ependymoma. The Classifier result (of
Fig. 7 EGFR amplification in IDH-wildtype glioblastoma: a, comparison of our dataset with a previously published dataset [39] shows that
the ratio of EGFR amplified and non-amplified, TERT-mutant GBM is similar to the published cohort (p = 0.3). Instead, the ratio of EGFR
amplified and non-amplified, TERT-wildtype GBM is different between both cohorts (p = 0.04). b, comparison of the prevalence of EGFR
status in GBM in our cohort (London, RT-PCR quantification) with those from the published dataset (“HD”, determined with the copy
number readout from the methylation arrays) [39], shows no statistically significant difference (χ2 2.3, p = 0.13). c, comparison of EGFR
status in our cohort determined with Illumina arrays and with RT-PCR. There is a 95% concordance between both methods (χ2 0.21, p =
0.64). EGFR was determined as amplified by RT-PCR where 6 and more copies were calculated with the CopyCaller™ software. EGFR data
extracted from the copy number variation plot (downloadable from www.molecularneuropathology.org) were called amplified if the
intensity was higher than 0.6 on a log2-scale [39]
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anaplastic) PXA prompted us to test for, and confirm
the BRAF V600E mutation, and the patient under-
went treatment with BRAF inhibitors. Another
tumour with histological features of anaplastic epen-
dymoma was reclassified as H3 K27M-mutant diffuse
midline glioma, and this mutation was confirmed sub-
sequently by IHC and H3F3A gene sequencing.
Conclusion
We report here a single centre experience of the im-
plementation of methylation arrays into routine prac-
tice for algorithmic classification of brain tumours. In
contrast to a paediatric setting, where a significant
proportion of tumours undergoes methylation-based
classification for risk stratification (such as ependy-
moma, medulloblastoma), methylation profiling for
this purpose constitutes only a minority of our ana-
lysis of adult brain tumours. The combination of
histological assessment with conventional molecular
testing (i.e. IHC, targeted sequencing, copy number
assay) is in our practice the first line diagnostic ap-
proach and is adequate for the majority of intrinsic
tumours, such as IDH-mutant astrocytomas, oligo-
dendrogliomas, histone-mutant, or EGFR-amplified,
TERT promoter-mutant IDH-wildtype glioblastomas.
By far the most common reason for using the
methylation-based classification in adult practice is
the need to obtain a more accurate and clinically
Fig. 8 Diagnostic testing algorithm for gliomas in adults. The first layer is the histological assessment. The histological identification of a glial
tumour is followed by the standard application of the antibodies IDH1 (R132H) and ATRX. This identifies a majority of IDH-mutant gliomas
(column 1, 2). IDH-mutant astrocytomas with ATRX loss are further tested for CDKN2A/B homozygous deletion to stratify high risk from lower risk
astrocytomas (column 1). Lower risk IDH-mutant astrocytomas are also assessed for copy number variation, a suggested prognostic factor. This is
achieved by the readout of the copy number variation (CNV) component of the methylation arrays. IDH-mutant gliomas with retained ATRX
expression (column 2) are further tested for 1p/19q co-deletion with a conventional copy number assay (in our practice combined with TERT
promoter mutation analysis). Those IDH-mutant tumours which have retained ATRX expression and either no co-deletion or an ambiguous copy
number result, are further tested with methylation array. This helps to differentiate IDH-mutant oligodendrogliomas from IDH-mutant
astrocytomas or glioblastomas with retained ATRX protein expression. Gliomas which are negative for IDH1 R132H are further tested for a panel
of biomarkers: IDH1, IDH2, H3 K27 and G34, BRAF, TERT promoter, EGFR and CDKN2A/B. IDH-mutant gliomas are shown in columns 3–5. The
subsequent testing algorithm in column 3 is the same as in column 1. The outcomes from histone mutation testing are in columns 6, 7. A
significant proportion of IDH-wildtype, EGFR-amplified and TERT promoter mutant glioblastomas are represented in column 8. These molecular
entities do not require further testing at present. Also, the detection of a BRAF V600E mutation usually does not require further methylation array
analysis (column 9). Those glial tumours with unequivocal histology (e.g. DNET, RGNT, ganglioglioma, IDH-wildtype GBM) are usually not further
tested. Instead, those with non-characteristic and non-specific low-grade or high-grade histology and inconclusive molecular profile undergo
methylation array analysis to inform of the methylation class which may also suggest candidate mutations that can be further tested for
subsequent validation, such as rare mutations in histone variant encoding genes other than H3F3A (column 10). Often the methylation analysis
also serves as a risk stratifier
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relevant diagnosis for tumours with unusual,
non-specific or non-representative histology and
where the molecular testing does not yield diagnostic-
ally informative results. We found a change of diag-
nosis in approximately 25% of patients, refinement in
approximately 50% and confirmation of the diagnosis
in 25%. In a proportion of cases where the diagnosis
changed, there was a significant impact on treatment
and clinical management, and in others, the provision
of accurate integrated diagnosis prevented from
Fig. 9 Diagnostic algorithm for ependymomas. In our diagnostic practice ependymomas in adults are infrequent. We first stratify the
tumours by location and histological appearance. Identification of subependymomas is histologically straightforward and these tumours
undergo no further testing (column 1). Supra- and infra-tentorial ependymomas are directly tested with methylation array (column 2).
RELA and YAP fusions (and p65 and L1CAM IHC) may be further tested depending on the Classifier result. In our practice, EPN_PF_A are
practically non-existent in the adult population, but H3 K27me3 expression status is technically straightforward and affordable and can
be tested with IHC for completeness. A small proportion of supratentorial ependymomas with “classical” histology may be reclassified
as subependymoma. Spinal tumours (column 3) are clinically low risk and their outcome is mainly determined by the extent of the
surgical removal. Unless there is a specific clinical need or unusual histology, spinal tumours are not further tested with methylation
arrays. Abbreviations: EPN_ST_SE: supratentorial subependymoma; EPN_PF_SE: posterior fossa subependymoma; EPN_ST_RELA:
supratentorial ependymoma with RELA fusion; EPN_ST_YAP: supratentorial ependymoma with YAP fusion; EPN_PF_A: posterior fossa
ependymoma group A; EPN_PF_B: posterior fossa ependymoma group B; EPN_SP_SE: spinal subependymoma; EPN_SP_E: spinal
ependymoma; EPN_SP_MPE: spinal myxopapillary ependymoma
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unnecessary, potentially harmful treatment. Our co-
hort further highlights the essential role of the methy-
lation array as a diagnostic tool in advanced brain
tumour diagnostics, when integrated into the diagnos-
tic pathway in a structured fashion as outlined in Fig.
8 and Fig. 9.
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